Manufacture of an aqueous intramuscular suspension of procaine penicillin G starts from micronised active substance whose particle-size distribution is controlled because syringeability through a 21-gauge needle and depot retention after deep gluteal injection depend on particle geometry and suspension rheology. The batch formula for a 300,000 IU/mL presentation is based on the anhydrous potency of procaine penicillin G, which is not less than 1,000 IU/mg; a compendial batch therefore charges 300 mg/g of active substance before assay correction against USP <81> or Ph. Eur. 2.6.1. Suspension-forming excipients are limited to those with published compatibility under beta-lactam storage conditions: sodium carboxymethylcellulose 0.5–1.5% w/v, polysorbate 80 0.1–0.3% w/v, and sodium chloride 0.9% w/v as tonicity modifier, with pH adjusted to 5.0–7.5 using citric acid/sodium citrate. The downstream process proceeds by high-shear rotor-stator dispersion, followed by wet-milling in a horizontal bead mill charged with 0.4–0.7 mm yttrium-stabilised zirconia beads at 65–85% chamber loading; terminal steam sterilisation is not possible because procaine penicillin G degrades above 40°C, and the suspension cannot be sterile-filtered through 0.22 µm membranes. Aseptic filling is therefore performed in an ISO 14644-1:2015 Class 5 zone using a rotary piston pump, with in-line laser diffraction verification of volume median diameter. Production-scale failure modes include bead-mill media loss below 60% chamber loading, which shifts D90 beyond 20 µm and produces intermittent syringe clogging on fill lines. The release testing matrix includes USP <71>, USP <85>, USP <788>, and USP <81>. Terminal product type is a ready-to-use sterile suspension for intramuscular administration in 2 mL or 4 mL vials. Intravenous administration is contraindicated because the procaine moiety can induce seizure-like activity and cardiac arrest; this boundary is stated in 21 CFR 201.57 labelling obligations.

What Controls the Reconstitution Time of Procaine Penicillin G Dry Powder for Injection?

Reconstitution time in dry powder vial presentations is governed by the porosity and residual moisture of the aseptic powder bed, not by the intrinsic aqueous solubility of the procaine salt. A dry powder formulation for injection is typically filled to deliver 600,000 IU or 1,200,000 IU per vial, with active substance comprising 70–95% w/w, lecithin 1–5% w/w as wetting agent, and anhydrous sodium citrate 1–3% w/w as buffer; residual moisture is held below 1.0% w/w by Karl Fischer titration because hydrolytic opening of the beta-lactam ring accelerates when water activity exceeds 0.3 during storage. Sterile procaine penicillin G is crystallised from acetone/water and vacuum-dried at product temperature not exceeding 40°C, then micronised with dry nitrogen gas. The powder is blended in a V-blender and filled on a gravimetric powder-filling line under low-humidity conditions of RH <20%. Terminal product type is a powder for injection that is reconstituted with Water for Injection to 300,000 IU/mL immediately before deep intramuscular use. The key compendial obligations remain USP <1>, USP <71>, USP <85>, USP <788>, and EU GMP Annex 1; container closure integrity is verified according to USP <1207>. Published data for a single universal reconstitution time specification are limited because the mass transfer rate depends on vial headspace geometry and the specific surface area of the micronised powder; release testing therefore uses an in-house wetting test with a 21-gauge needle and 20 mL diluent volume.

In oral veterinary water-dispersible granulate lines, procaine penicillin G is adsorbed onto a lactose or glucose carrier because the neat API has high static charge and poor flowability when metered into drinking-water systems. A commercial premix often carries 100,000 IU/g active loading, corresponding to approximately 10% w/w procaine penicillin G, with lactose monohydrate 80–88% w/w, povidone 2–5% w/w as binder, and citric acid 1–2% w/w to lower reconstitution pH and reduce beta-lactam hydrolysis during stand time in water lines. Fluid-bed top-spray granulation is run with inlet air 50–65°C, product temperature below 40°C, and final moisture below 2.0% w/w; the dried granulate is screened to 16–60 mesh fractions to ensure rapid dispersion. Terminal product type is a water-dispersible oral granule packed in 1 kg or 5 kg foil-lined sacks for in-line medication of poultry or swine drinking water. The regulatory basis in the European Union is Regulation (EU) 2019/6 for veterinary medicinal products, and in the United States the medicated feed route is addressed under 21 CFR 558 with a Type A medicated article registration; microbial limits are assessed by USP <2021> or Ph. Eur. 2.6.12. A critical operating boundary is that procaine penicillin G does not form a true solution; the dosing tank requires constant agitation to avoid sedimentation and variable intake in the flock or herd.

Intramammary Infusion Suspensions for Bovine Mastitis: 300 000 IU Syringe Conformation

Bovine intramammary infusion lines require a 300,000 IU active load per 10 g syringe, equivalent to 3% w/w procaine penicillin G when the assay is 1,000 IU/mg. The vehicle is typically a sterile oil or aqueous gel; oil-based systems use peanut or fractionated coconut oil with 2–5% w/w aluminium monostearate as thixotropic agent, while aqueous systems use sodium alginate or methylcellulose 1–3% w/w to prevent rapid drainage from the mammary cistern. Downstream manufacture proceeds by heat-sterilising the vehicle at 160–170°C for oil systems, cooling aseptically, and dispersing the pre-sterilised micronised API through a high-shear mixer; the bulk suspension is then filled into 10 mL intramammary syringes on a dedicated line under ISO 14644-1:2015 Class 5. Terminal product type is a single-use intramammary infusion for lactating cows; combination products with dihydrostreptomycin or neomycin are also common and invoke additional aminoglycoside-specific controls. Regulatory requirements include 21 CFR 526.1690 for new animal drug approvals, USP <71> and USP <85> for sterile veterinary injectables, and residue withdrawal periods set under VICH GL 48 or the relevant regional MRL regulation. A fundamental incompatibility is the destabilisation of procaine penicillin G by tetracycline or aminoglycoside salts in the same syringe unless the manufacturer specifically validates the combination stability at 2–8°C for the labelled shelf life.

Procaine/benzathine combination injectable suspensions require separate particle-size control for the two penicillin G salts because the procaine component releases within 12–24 h while the benzathine component provides depot release over 7 days; blending therefore creates a biphasic absorption profile that cannot be inferred from a single-salt suspension. A common clinical ratio is 300,000 IU procaine penicillin G combined with 900,000 IU benzathine penicillin G per 2 mL, giving a procaine fraction of 25% of total units; the total active solids may reach 35–45% w/w depending on the potency of each salt. Downstream preparation requires separate micronisation of procaine and benzathine salts to different volume mean diameters, followed by suspending in a citrate-buffered vehicle with 0.5–1.5% w/v sodium carboxymethylcellulose and 0.1–0.3% w/v polysorbate 80; the two APIs are not co-milled because differential fracture behaviour shifts the release ratio. Aseptic filling on a reciprocating piston line is followed by gentle end-over-end mixing rather than high-shear blending to prevent particle aggregation. Terminal product type is a ready-to-use dual-salt intramuscular suspension used for streptococcal pharyngitis and syphilis in outpatient settings. The compendial framework includes USP <1>, USP <71>, USP <85>, USP <788>, USP <81>, and 21 CFR 210/211; in-process testing must verify procaine content separately from benzathine content by HPLC or UV derivative spectroscopy, because total penicillin G potency alone is insufficient to control the biphasic ratio. A critical limitation is that the procaine component must never be administered intravenously, and the suspension must be resuspended by vigorous shaking immediately before injection to avoid non-uniform dosing.

When Oral Tablet or Capsule Bioavailability Is Assessed, Enteric Protection Governs Procaine Penicillin G Dosing

When a procaine penicillin G tablet or capsule is developed under a national veterinary marketing authorisation, the formulation must manage acid lability and low dissolution at gastric pH rather than simply meeting potency limits. A development-scale dry granulation formula charges 60–80% w/w API, 10–20% w/w microcrystalline cellulose, 2–5% w/w croscarmellose sodium, and 0.5–1.5% w/w magnesium stearate; the granulate is compacted at 8–15 kN on a rotary tablet press. An enteric coating of 8–12% w/w weight gain using methacrylic acid copolymer or hypromellose phthalate is applied in a pan coater at product temperature 28–32°C. For capsules, the same granulate is filled into hard gelatin shells and then enteric-coated as multiparticulates or as whole capsules. Terminal product type is an enteric-coated tablet or hard gelatin capsule intended for oral administration in companion-animal or production-animal markets where parenteral administration is not feasible. The dissolution specification is set by USP <711> using 0.1 M HCl acid stage for 2 h followed by pH 6.8 phosphate buffer; disintegration follows USP <2040> or Ph. Eur. 2.9.1. Published data for the oral bioavailability of procaine penicillin G tablets are limited, and most human and veterinary formularies prefer phenoxymethylpenicillin for oral beta-lactam therapy; therefore this route is only applied where parenteral alternatives are not accepted. The principal incompatibility is with moisture during granulation; aqueous granulation is avoided unless the API is protected by a hydrophobic pre-coat.